

Walter J Storkus

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1898024/publications.pdf>

Version: 2024-02-01

160
papers

8,660
citations

34105

52
h-index

49909

87
g-index

162
all docs

162
docs citations

162
times ranked

8734
citing authors

#	ARTICLE	IF	CITATIONS
1	Tumor-Derived Microvesicles Promote Regulatory T Cell Expansion and Induce Apoptosis in Tumor-Reactive Activated CD8+ T Lymphocytes. <i>Journal of Immunology</i> , 2009, 183, 3720-3730.	0.8	479
2	Î±-Type-1 Polarized Dendritic Cells. <i>Cancer Research</i> , 2004, 64, 5934-5937.	0.9	449
3	Dendritic Cells Mediate NK Cell Help for Th1 and CTL Responses: Two-Signal Requirement for the Induction of NK Cell Helper Function. <i>Journal of Immunology</i> , 2003, 171, 2366-2373.	0.8	326
4	Disease-associated Bias in T Helper Type 1 (Th1)/Th2 CD4+ T Cell Responses Against MAGE-6 in HLA-DRB1*0401+ Patients With Renal Cell Carcinoma or Melanoma. <i>Journal of Experimental Medicine</i> , 2002, 196, 619-628.	8.5	290
5	Immunopolarization of CD4+ and CD8+ T Cells to Type-1-â€œLike is Associated with Melanocyte Loss in Human Vitiligo. <i>Laboratory Investigation</i> , 2003, 83, 683-695.	3.7	212
6	Identification of T-Cell Epitopes. <i>Journal of Immunotherapy</i> , 1993, 14, 94-103.	2.4	210
7	FLT3 Ligand Induces the Generation of Functionally Active Dendritic Cells in Mice. <i>Cellular Immunology</i> , 1997, 179, 174-184.	3.0	199
8	STING Agonists as Cancer Therapeutics. <i>Cancers</i> , 2021, 13, 2695.	3.7	181
9	Complementary Dendritic Cell-â€œactivating Function of CD8+ and CD4+ T Cells. <i>Journal of Experimental Medicine</i> , 2002, 195, 473-483.	8.5	167
10	Toll like receptor-3 ligand poly-ICLC promotes the efficacy of peripheral vaccinations with tumor antigen-derived peptide epitopes in murine CNS tumor models. <i>Journal of Translational Medicine</i> , 2007, 5, 10.	4.4	161
11	Interleukin-12 and B7.1 co-stimulation cooperate in the induction of effective antitumor immunity and therapy of established tumors. <i>European Journal of Immunology</i> , 1996, 26, 1335-1341.	2.9	135
12	Construction and Characterization of Retroviral Vectors Expressing Biologically Active Human Interleukin-12. <i>Human Gene Therapy</i> , 1994, 5, 1493-1506.	2.7	131
13	Mature dendritic cells pulsed with freeze-thaw cell lysates define an effective in vitro vaccine designed to elicit EBV-specific CD4+ and CD8+ T lymphocyte responses. <i>Blood</i> , 2000, 96, 1857-1864.	1.4	129
14	Innate Direct Anticancer Effector Function of Human Immature Dendritic Cells. II. Role of TNF, Lymphotoxin-Î±, IL-12, Fas Ligand, and TNF-Related Apoptosis-Inducing Ligand. <i>Journal of Immunology</i> , 2002, 168, 1831-1839.	0.8	128
15	Sunitinib facilitates the activation and recruitment of therapeutic anti-tumor immunity in concert with specific vaccination. <i>International Journal of Cancer</i> , 2011, 129, 2158-2170.	5.1	127
16	EphA2 as a Glioma-Associated Antigen: A Novel Target for Glioma Vaccines. <i>Neoplasia</i> , 2005, 7, 717-722.	5.3	126
17	Genetically modified bone marrow-derived dendritic cells expressing tumor-associated viral or â€œselfâ€œ-antigens induce antitumor immunity in vivo. <i>European Journal of Immunology</i> , 1997, 27, 2702-2707.	2.9	119
18	Disease stage variation in CD4+ and CD8+ T-cell reactivity to the receptor tyrosine kinase EphA2 in patients with renal cell carcinoma. <i>Cancer Research</i> , 2003, 63, 4481-9.	0.9	110

#	ARTICLE	IF	CITATIONS
19	Alterations in the frequency of dendritic cell subsets in the peripheral circulation of patients with squamous cell carcinomas of the head and neck. <i>Clinical Cancer Research</i> , 2002, 8, 1787-93.	7.0	106
20	Epigenetic modulation of antitumor immunity for improved cancer immunotherapy. <i>Molecular Cancer</i> , 2021, 20, 171.	19.2	106
21	Intratumoral delivery of dendritic cells engineered to secrete both interleukin (IL)-12 and IL-18 effectively treats local and distant disease in association with broadly reactive Tc1-type immunity. <i>Cancer Research</i> , 2003, 63, 6378-86.	0.9	105
22	Identification of a novel HLA-A*0201-restricted, cytotoxic T lymphocyte epitope in a human glioma-associated antigen, interleukin 13 receptor alpha2 chain. <i>Clinical Cancer Research</i> , 2002, 8, 2851-5.	7.0	99
23	Helper role of NK cells during the induction of anticancer responses by dendritic cells. <i>Molecular Immunology</i> , 2005, 42, 535-539.	2.2	98
24	IL-36 β Transforms the Tumor Microenvironment and Promotes Type 1 Lymphocyte-Mediated Antitumor Immune Responses. <i>Cancer Cell</i> , 2015, 28, 296-306.	16.8	93
25	DNA Immunization Targeting the Skin: Molecular Control of Adaptive Immunity. <i>Journal of Investigative Dermatology</i> , 1998, 111, 183-188.	0.7	91
26	Evaluation of the Modified ELISPOT Assay for Gamma Interferon Production in Cancer Patients Receiving Antitumor Vaccines. <i>Vaccine Journal</i> , 2000, 7, 145-154.	2.6	88
27	IL-12-Engineered Dendritic Cells Serve as Effective Tumor Vaccine Adjuvants in Vivo. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 284-293.	3.8	85
28	Adoptive Transfer of Type 1 CTL Mediates Effective Anti-Central Nervous System Tumor Response: Critical Roles of IFN-Inducible Protein-10. <i>Cancer Research</i> , 2006, 66, 4478-4487.	0.9	84
29	Polarized Type-1 Dendritic Cells (DC1) Producing High Levels of IL-12 Family Members Rescue Patient TH1-type Antimelanoma CD4+ T cell Responses In Vitro. <i>Journal of Immunotherapy</i> , 2007, 30, 75-82.	2.4	81
30	Innate Direct Anticancer Effector Function of Human Immature Dendritic Cells. I. Involvement of an Apoptosis-Inducing Pathway. <i>Journal of Immunology</i> , 2002, 168, 1823-1830.	0.8	80
31	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 111-121.	4.2	71
32	Flow-cytometric determination of peptide-class I complex formation identification of p53 peptides that bind to HLA-A2. <i>Human Immunology</i> , 1994, 39, 79-86.	2.4	70
33	Cytokine Gene Therapy of Cancer Using Interleukin-12: Murine and Clinical Trials. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 440-454.	3.8	70
34	Induction of tumor antigen-specific immunity using plasmid DNA immunization in mice. <i>Cancer Gene Therapy</i> , 1999, 6, 73-80.	4.6	69
35	Effect of Renal Cell Carcinomas on the Development of Type 1 T-Cell Responses. <i>Clinical Cancer Research</i> , 2004, 10, 6360S-6366S.	7.0	69
36	Tumor-Derived Vascular Pericytes Anergize Th Cells. <i>Journal of Immunology</i> , 2013, 191, 971-981.	0.8	69

#	ARTICLE	IF	CITATIONS
37	Gene-based strategies for the immunotherapy of cancer. <i>Journal of Molecular Medicine</i> , 1997, 75, 478-491.	3.9	67
38	IL-12 Gene Therapy Using Direct Injection of Tumors with Genetically Engineered Autologous Fibroblasts. University of Pittsburgh, Pittsburgh, Pennsylvania. <i>Human Gene Therapy</i> , 1995, 6, 1607-1624.	2.7	66
39	Expression of EphA2 is prognostic of disease-free interval and overall survival in surgically treated patients with renal cell carcinoma. <i>Clinical Cancer Research</i> , 2005, 11, 226-31.	7.0	66
40	Identification of wild-type and mutant p53 peptides binding to HLA-A2 assessed by a peptide loading-deficient cell line assay and a novel major histocompatibility complex class I peptide binding assay. <i>European Journal of Immunology</i> , 1994, 24, 765-768.	2.9	65
41	Dendritic Cell/Peptide Cancer Vaccines: Clinical Responsiveness and Epitope Spreading. <i>Immunological Investigations</i> , 2000, 29, 121-125.	2.0	61
42	Preferential Expression of Very Late Antigen-4 on Type 1 CTL Cells Plays a Critical Role in Trafficking into Central Nervous System Tumors. <i>Cancer Research</i> , 2007, 67, 6451-6458.	0.9	60
43	Tumor-derived exosomes promote carcinogenesis of murine oral squamous cell carcinoma. <i>Carcinogenesis</i> , 2020, 41, 625-633.	2.8	60
44	Identification of Interleukin-13 Receptor β 2 Peptide Analogues Capable of Inducing Improved Antiglioma CTL Responses. <i>Cancer Research</i> , 2006, 66, 5883-5891.	0.9	59
45	Combined vaccine+axitinib therapy yields superior antitumor efficacy in a murine melanoma model. <i>Melanoma Research</i> , 2012, 22, 236-243.	1.2	59
46	Tbet and IL-36 β cooperate in therapeutic DC-mediated promotion of ectopic lymphoid organogenesis in the tumor microenvironment. <i>Oncolmmunology</i> , 2017, 6, e1322238.	4.6	59
47	Association of IL-36 β with tertiary lymphoid structures and inflammatory immune infiltrates in human colorectal cancer. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 109-120.	4.2	59
48	Proinflammatory Cytokines and CD40 Ligand Enhance Cross-Presentation and Cross-Priming Capability of Human Dendritic Cells Internalizing Apoptotic Cancer Cells. <i>Journal of Immunotherapy</i> , 2001, 24, 162-171.	2.4	57
49	Ectopic Expression of Interferon Regulatory Factor-1 Promotes Human Breast Cancer Cell Death and Results in Reduced Expression of Survivin. <i>Cancer Research</i> , 2004, 64, 8381-8388.	0.9	57
50	Neurokinin-1 receptor agonists bias therapeutic dendritic cells to induce type 1 immunity by licensing host dendritic cells to produce IL-12. <i>Blood</i> , 2013, 121, 2923-2933.	1.4	57
51	STING agonist-based treatment promotes vascular normalization and tertiary lymphoid structure formation in the therapeutic melanoma microenvironment. , 2021, 9, e001906.		57
52	Vaccination with EphA2-derived T cell-epitopes promotes immunity against both EphA2-expressing and EphA2-negative tumors. <i>Journal of Translational Medicine</i> , 2004, 2, 40.	4.4	56
53	Delivery of Dendritic Cells Engineered to Secrete IFN β into Central Nervous System Tumors Enhances the Efficacy of Peripheral Tumor Cell Vaccines: Dependence on Apoptotic Pathways. <i>Journal of Immunology</i> , 2005, 175, 2730-2740.	0.8	54
54	Nitric Oxide Sensitizes Tumor Cells to Dendritic Cell-Mediated Apoptosis, Uptake, and Cross-Presentation. <i>Cancer Research</i> , 2005, 65, 8461-8470.	0.9	54

#	ARTICLE	IF	CITATIONS
55	Chronic inflammation and immunologic-based constraints in malignant disease. <i>Immunotherapy</i> , 2011, 3, 1265-1274.	2.0	53
56	Melanocyte-Specific Immune Response in Melanoma and Vitiligo: Two Faces of the Same Coin?. <i>Pigment Cell & Melanoma Research</i> , 2003, 16, 254-260.	3.6	52
57	Combination Therapy with HSP90 Inhibitor 17-DMAG Reconditions the Tumor Microenvironment to Improve Recruitment of Therapeutic T cells. <i>Cancer Research</i> , 2012, 72, 3196-3206.	0.9	52
58	Combined VLA-4-Targeted Radionuclide Therapy and Immunotherapy in a Mouse Model of Melanoma. <i>Journal of Nuclear Medicine</i> , 2018, 59, 1843-1849.	5.0	52
59	Immunotherapy of murine colon cancer using receptor tyrosine kinase EphA2-derived peptide-pulsed dendritic cell vaccines. <i>Cancer</i> , 2007, 110, 1469-1477.	4.1	49
60	Therapeutic Lymphoid Organogenesis in the Tumor Microenvironment. <i>Advances in Cancer Research</i> , 2015, 128, 197-233.	5.0	45
61	Third Keystone Symposium on Cellular Immunology and the Immunotherapy of Cancer Antigen Processing and Presentation Autologous Human Dendriphages Pulsed with Synthetic or Natural Tumor Peptides Elicit Tumor-Specific CTLs In Vitro. <i>Journal of Immunotherapy</i> , 1998, 21, 149.	2.4	44
62	Vaccines Targeting Tumor Blood Vessel Antigens Promote CD8+ T Cell-Dependent Tumor Eradication or Dormancy in HLA-A2 Transgenic Mice. <i>Journal of Immunology</i> , 2012, 188, 1782-1788.	0.8	44
63	Interferon-alpha (IFN- α)-conditioned DC Preferentially Stimulate Type-1 and Limit Treg-type In Vitro T-cell Responses From RCC Patients. <i>Journal of Immunotherapy</i> , 2008, 31, 254-262.	2.4	43
64	Interleukin 18 gene transfer expands the repertoire of antitumor Th1-type immunity elicited by dendritic cell-based vaccines in association with enhanced therapeutic efficacy. <i>Cancer Research</i> , 2002, 62, 5853-8.	0.9	43
65	Intratumoral IL-12 Gene Therapy Results in the Crosspriming of Tc1 Cells Reactive Against Tumor-associated Stromal Antigens. <i>Molecular Therapy</i> , 2011, 19, 805-814.	8.2	41
66	Delivery of Interferon- α Transfected Dendritic Cells into Central Nervous System Tumors Enhances the Antitumor Efficacy of Peripheral Peptide-Based Vaccines. <i>Cancer Research</i> , 2004, 64, 5830-5838.	0.9	40
67	A Therapeutic OX40 Agonist Dynamically Alters Dendritic, Endothelial, and T Cell Subsets within the Established Tumor Microenvironment. <i>Cancer Research</i> , 2010, 70, 9041-9052.	0.9	40
68	Dendritic Cell Based Therapy of Cancer. <i>Advances in Experimental Medicine and Biology</i> , 1997, 417, 551-569.	1.6	40
69	Dasatinib promotes the expansion of a therapeutically superior T-cell repertoire in response to dendritic cell vaccination against melanoma. <i>Oncolmmunology</i> , 2014, 3, e27589.	4.6	38
70	Myeloid-derived Suppressor Cells Adhere to Physiologic STAT3- vs STAT5-dependent Hematopoietic Programming, Establishing Diverse Tumor-Mediated Mechanisms of Immunologic Escape. <i>Immunological Investigations</i> , 2012, 41, 680-710.	2.0	37
71	Tumor-associated mesenchymal stem cells inhibit na \bar{v} e T cell expansion by blocking cysteine export from dendritic cells. <i>International Journal of Cancer</i> , 2016, 139, 2068-2081.	5.1	37
72	Heat Shock Protein 90 Inhibitor 17-Dimethylaminoethylamino-17-Demethoxygeldanamycin Enhances EphA2+ Tumor Cell Recognition by Specific CD8+ T Cells. <i>Cancer Research</i> , 2009, 69, 6995-7003.	0.9	36

#	ARTICLE	IF	CITATIONS
73	Application of IL-5 ELISPOT assays to quantification of antigen-specific T helper responses. <i>Journal of Immunological Methods</i> , 2002, 261, 145-156.	1.4	35
74	Genetic Vaccines To Potentiate the Effective CD103+ Dendritic Cell-Mediated Cross-Priming of Antitumor Immunity. <i>Journal of Immunology</i> , 2015, 194, 5937-5947.	0.8	35
75	Murine Models of Cancer Cytokine Gene Therapy Using Interleukin-12. <i>Annals of the New York Academy of Sciences</i> , 1996, 795, 275-283.	3.8	34
76	IL-4-Transfected Tumor Cell Vaccines Activate Tumor-Infiltrating Dendritic Cells and Promote Type-1 Immunity. <i>Journal of Immunology</i> , 2005, 174, 7194-7201.	0.8	34
77	miR-29b and miR-198 overexpression in CD8+ T cells of renal cell carcinoma patients down-modulates JAK3 and MCL-1 leading to immune dysfunction. <i>Journal of Translational Medicine</i> , 2016, 14, 84.	4.4	34
78	Interleukin-12 Gene Therapy Prevents Establishment of SCC VII Squamous Cell Carcinomas, Inhibits Tumor Growth, and Elicits Long-term Antitumor Immunity in Syngeneic C3H Mice. <i>Laryngoscope</i> , 1998, 108, 261-268.	2.0	32
79	A Mycoplasma Peptide Elicits Heteroclitic CD4+ T Cell Responses against Tumor Antigen MAGE-A6. <i>Clinical Cancer Research</i> , 2007, 13, 6796-6806.	7.0	32
80	CD8+ T-Cell Responses against Hemoglobin- β Prevent Solid Tumor Growth. <i>Cancer Research</i> , 2008, 68, 8076-8084.	0.9	31
81	Ectopic T-bet Expression Licenses Dendritic Cells for IL-12-Independent Priming of Type 1 T Cells In Vitro. <i>Journal of Immunology</i> , 2009, 183, 7250-7258.	0.8	30
82	Single injection of IL-12 coacervate as an effective therapy against B16-F10 melanoma in mice. <i>Journal of Controlled Release</i> , 2020, 318, 270-278.	9.9	30
83	Effective induction of antglioma cytotoxic T cells by coadministration of interferon- γ gene vector and dendritic cells. <i>Cancer Gene Therapy</i> , 2003, 10, 549-558.	4.6	29
84	Disease-Stage Variance in Functional CD4+ T-Cell Responses Against Novel Pan-Human Leukocyte Antigen-D Region Presented Human Papillomavirus-16 E7 Epitopes. <i>Clinical Cancer Research</i> , 2004, 10, 3301-3308.	7.0	29
85	EBV-specific memory CD8+ T cell phenotype and function in stable solid organ transplant patients. <i>Transplant Immunology</i> , 2005, 14, 109-116.	1.2	28
86	Enhancement in Specific CD8+ T Cell Recognition of EphA2+ Tumors In Vitro and In Vivo after Treatment with Ligand Agonists. <i>Journal of Immunology</i> , 2008, 181, 7721-7727.	0.8	28
87	Stat6 Signaling Suppresses VLA-4 Expression by CD8+ T Cells and Limits Their Ability to Infiltrate Tumor Lesions In Vivo. <i>Journal of Immunology</i> , 2008, 181, 104-108.	0.8	28
88	DLK1: A Novel Target for Immunotherapeutic Remodeling of the Tumor Blood Vasculature. <i>Molecular Therapy</i> , 2013, 21, 1958-1968.	8.2	28
89	Combinational FLT3 Ligand and Granulocyte Macrophage Colony-Stimulating Factor Treatment Promotes Enhanced Tumor Infiltration by Dendritic Cells and Antitumor CD8+ T-Cell Cross-priming but Is Ineffective as a Therapy. <i>Cancer Research</i> , 2006, 66, 4895-4903.	0.9	27
90	Helper Function of Memory CD8+ T Cells: Heterologous CD8+ T Cells Support the Induction of Therapeutic Cancer Immunity. <i>Cancer Research</i> , 2007, 67, 10012-10018.	0.9	27

#	ARTICLE	IF	CITATIONS
91	EX VIVO GENERATION OF EFFECTIVE EPSTEIN-BARR VIRUS (EBV)-SPECIFIC CD8+ CYTOTOXIC T LYMPHOCYTES FROM THE PERIPHERAL BLOOD OF IMMUNOCOMPETENT EPSTEIN BARR VIRUS-SERONEGATIVE INDIVIDUALS1. Transplantation, 2000, 70, 1507-1515.	1.0	26
92	IL-4 Suppresses Very Late Antigen-4 Expression Which is Required for Therapeutic Th1 T-cell Trafficking Into Tumors. Journal of Immunotherapy, 2009, 32, 793-802.	2.4	25
93	Therapeutic Use of Dendritic Cells to Promote the Extranodal Priming of Anti-Tumor Immunity. Frontiers in Immunology, 2013, 4, 388.	4.8	25
94	Molecular mimicry of MAGE-A6 and <i>Mycoplasma penetrans</i> HF-2 epitopes in the induction of antitumor CD8 ⁺ T-cell responses. Oncoimmunology, 2014, 3, e954501.	4.6	25
95	A 'good death' for tumor immunology. Nature Medicine, 2007, 13, 28-30.	30.7	24
96	DC expressing transgene Foxp3 are regulatory APC. European Journal of Immunology, 2010, 40, 480-493.	2.9	24
97	Dendritic cell vaccines targeting tumor blood vessel antigens in combination with dasatinib induce therapeutic immune responses in patients with checkpoint-refractory advanced melanoma. , 2021, 9, e003675.		24
98	Ex Vivo Priming of Naïve T Cells Into EBV-Specific Th1/Tc1 Effector Cells by Mature Autologous DC Loaded with Apoptotic/Necrotic LCL. American Journal of Transplantation, 2003, 3, 1369-1377.	4.7	23
99	IL-4 inhibits VLA-4 expression on Tc1 cells resulting in poor tumor infiltration and reduced therapy benefit. European Journal of Immunology, 2008, 38, 2865-2873.	2.9	22
100	JAK3/STAT5/6 Pathway Alterations Are Associated with Immune Deviation in CD8 ⁺ T Cells in Renal Cell Carcinoma Patients. Journal of Biomedicine and Biotechnology, 2010, 2010, 1-13.	3.0	22
101	Intratumoral delivery of mTORC2-deficient dendritic cells inhibits B16 melanoma growth by promoting CD8 ⁺ effector T cell responses. Oncoimmunology, 2016, 5, e1146841.	4.6	21
102	RGS5-TGF β 2-Smad2/3 axis switches pro- to anti-apoptotic signaling in tumor-residing pericytes, assisting tumor growth. Cell Death and Differentiation, 2021, 28, 3052-3076.	11.2	21
103	Tumor-Derived Î±-Fetoprotein Directly Drives Human Natural Killer Cell Activation and Subsequent Cell Death. Cancer Immunology Research, 2017, 5, 493-502.	3.4	20
104	Circulating Type-1 Anti-Tumor CD4 ⁺ T Cells are Preferentially Pro-Apoptotic in Cancer Patients. Frontiers in Oncology, 2014, 4, 266.	2.8	19
105	Actin-binding protein profilin1 promotes aggressiveness of clear-cell renal cell carcinoma cells. Journal of Biological Chemistry, 2020, 295, 15636-15649.	3.4	18
106	Human Papillomavirus L1L2-E7 Virus-Like Particles Partially Mature Human Dendritic Cells and Elicit E7-Specific T-Helper Responses From Patients With Cervical Intraepithelial Neoplasia or Cervical Cancer In Vitro. Human Immunology, 2005, 66, 762-772.	2.4	17
107	Immunotherapeutic Targeting of Tumor-Associated Blood Vessels. Advances in Experimental Medicine and Biology, 2017, 1036, 191-211.	1.6	17
108	IL-12 Production by Human Monocyte-Derived Dendritic Cells. Journal of Immunotherapy, 2005, 28, 306-313.	2.4	16

#	ARTICLE	IF	CITATIONS
109	Biosynthesis and Functional Significance of Peripheral Node Addressin in Cancer-Associated TLO. <i>Frontiers in Immunology</i> , 2016, 7, 301.	4.8	16
110	STINGing the Tumor Microenvironment to Promote Therapeutic Tertiary Lymphoid Structure Development. <i>Frontiers in Immunology</i> , 2021, 12, 690105.	4.8	16
111	Dendritic cell-derived interleukin-15 is crucial for therapeutic cancer vaccine potency. <i>Oncolmmunology</i> , 2014, 3, e959321.	4.6	15
112	Dysregulated NF-ÎB-Dependent ICOSL Expression in Human Dendritic Cell Vaccines Impairs T-cell Responses in Patients with Melanoma. <i>Cancer Immunology Research</i> , 2020, 8, 1554-1567.	3.4	15
113	Focus on FOCIS: Interleukin 2 treatment associated autoimmunity. <i>Clinical Immunology</i> , 2008, 127, 123-129.	3.2	14
114	Integrating costimulatory agonists to optimize immune-based cancer therapies. <i>Immunotherapy</i> , 2009, 1, 249-264.	2.0	14
115	Generation of robust CD8 ⁺ T cell responses against subdominant epitopes in conserved regions of HIV-1 by repertoire mining with mimotopes. <i>European Journal of Immunology</i> , 2010, 40, 1950-1962.	2.9	14
116	Intralesional Delivery of Dendritic Cells Engineered to Express T-bet Promotes Protective Type 1 Immunity and the Normalization of the Tumor Microenvironment. <i>Journal of Immunology</i> , 2010, 185, 2895-2902.	0.8	14
117	Therapeutic efficacy of combined vaccination against tumor pericyte-associated antigens DLK1 and DLK2 in mice. <i>Oncolmmunology</i> , 2017, 6, e1290035.	4.6	14
118	Impact of combination immunochemotherapies on progression of 4NQO-induced murine oral squamous cell carcinoma. <i>Cancer Immunology, Immunotherapy</i> , 2019, 68, 1133-1141.	4.2	14
119	Dendritic cell-based vaccines and therapies for cancer. <i>Expert Opinion on Biological Therapy</i> , 2002, 2, 919-928.	3.1	13
120	Sensory Nerves Impede the Formation of Tertiary Lymphoid Structures and Development of Protective Antimelanoma Immune Responses. <i>Cancer Immunology Research</i> , 2022, 10, 1141-1154.	3.4	13
121	Augmentation of Type-1 Polarizing Ability of Monocyte-Derived Dendritic Cells from Chronically Immunosuppressed Organ-Transplant Recipients. <i>Transplantation</i> , 2005, 79, 451-459.	1.0	12
122	Intratumoral delivery of tumor antigen-loaded DC and tumor-primed CD4 ⁺ T cells combined with agonist Î±-GITR mAb promotes durable CD8 ⁺ T-cell-dependent antitumor immunity. <i>Oncolmmunology</i> , 2017, 6, e1315487.	4.6	12
123	IL-36 Signaling in the Tumor Microenvironment. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1240, 95-110.	1.6	11
124	Combination strategies to enhance the potency of monocyte-derived dendritic cell-based cancer vaccines. <i>Immunotherapy</i> , 2016, 8, 1205-1218.	2.0	10
125	Cutaneous Melanoma: Mutational Status and Potential Links to Tertiary Lymphoid Structure Formation. <i>Frontiers in Immunology</i> , 2021, 12, 629519.	4.8	10
126	Improving Immunotherapy by Conditionally Enhancing MHC Class I Presentation of Tumor Antigen-Derived Peptide Epitopes. <i>Critical Reviews in Immunology</i> , 2007, 27, 485-493.	0.5	10

#	ARTICLE	IF	CITATIONS
127	Giving DNA vaccines a helping hand. <i>Nature Medicine</i> , 1998, 4, 1239-1240.	30.7	8
128	Accumulation of low-avidity anti-melanocortin receptor 1 (anti-MC1R) CD8+ T cells in the lesional skin of a patient with melanoma-related depigmentation. <i>Melanoma Research</i> , 2006, 16, 165-174.	1.2	8
129	Treatment-Enhanced CD4+Foxp3+Glucocorticoid-Induced TNF Receptor Family RelatedHighRegulatory Tumor-Infiltrating T Cells Limit the Effectiveness of Cytokine-Based Immunotherapy. <i>Journal of Immunology</i> , 2007, 178, 3400-3408.	0.8	8
130	Combined Tbet and IL12 Gene Therapy Elicits and Recruits Superior Antitumor Immunity In Vivo. <i>Molecular Therapy</i> , 2012, 20, 644-651.	8.2	8
131	Class I-like CD1A-C Do Not Protect Target Cells from NK-Mediated Cytolysis. <i>Cellular Immunology</i> , 1996, 167, 154-156.	3.0	6
132	Amino acid substitutions at position 97 in HLA-A2 segregate cytolysis from cytokine release in MART-1/Melan-A peptide AAGIGILTV-specific cytotoxic T lymphocytes. <i>European Journal of Immunology</i> , 1996, 26, 2613-2623.	2.9	6
133	Shock block for improved immunotherapy. <i>Oncolmmunology</i> , 2012, 1, 1427-1429.	4.6	6
134	Host immune response in renal cell cancer: Interleukin-4 (IL-4) and IL-10 mRNA are frequently detected in freshly collected tumor-infiltrating lymphocytes. <i>Cancer Immunology, Immunotherapy</i> , 1995, 41, 111-121.	4.2	6
135	Improved prognosis and evidence of enhanced immunogenicity in tumor and circulation of high-risk melanoma patients with unknown primary. , 2022, 10, e004310.		6
136	Progenipoiectin-generated dendritic cells exhibit anti-tumor efficacy in a therapeutic murine tumor model. <i>International Journal of Cancer</i> , 2002, 100, 586-591.	5.1	5
137	Inhibiting Autophagy in Renal Cell Cancer and the Associated Tumor Endothelium. <i>Cancer Journal (Sudbury, Mass)</i> , 2019, 25, 165-177.	2.0	5
138	Tumor Arrests DN2 to DN3 Pro T Cell Transition and Promotes Its Conversion to Thymic Dendritic Cells by Reciprocally Regulating Notch1 and Ikaros Signaling. <i>Frontiers in Immunology</i> , 2020, 11, 898.	4.8	5
139	Enhanced immune activation within the tumor microenvironment and circulation of female high-risk melanoma patients and improved survival with adjuvant CTLA4 blockade compared to males. <i>Journal of Translational Medicine</i> , 2022, 20, .	4.4	5
140	The Immunology of DNA Vaccines. , 2000, 29, 37-64.		4
141	Vaccine therapy + dasatinib for the treatment of patients with stage III&IV melanoma. <i>Melanoma Management</i> , 2016, 3, 251-254.	0.5	4
142	Update on vaccine development for renal cell cancer. <i>Research and Reports in Urology</i> , 2010, Volume 2, 125-141.	1.0	3
143	Unbiased High-Throughput Drug Combination Pilot Screening Identifies Synergistic Drug Combinations Effective against Patient-Derived and Drug-Resistant Melanoma Cell Lines. <i>SLAS Discovery</i> , 2021, 26, 712-729.	2.7	3
144	CD40 Cross-Linking Induces Migration of Renal Tumor Cell through Nuclear Factor of Activated T Cells (NFAT) Activation. <i>International Journal of Molecular Sciences</i> , 2021, 22, 8871.	4.1	3

#	ARTICLE	IF	CITATIONS
145	PET Imaging of VLA-4 in a New BRAFV600E Mouse Model of Melanoma. <i>Molecular Imaging and Biology</i> , 2022, 24, 425-433.	2.6	3
146	Report on the ISBTC Mini-symposium on Biologic Effects of Targeted Therapeutics. <i>Journal of Immunotherapy</i> , 2007, 30, 577-590.	2.4	2
147	Skin immunization for effective treatment of multifocal melanoma refractory to PD1 blockade and Braf inhibitors. , 2021, 9, e001179.		2
148	Monitoring Antigen-Specific T Cell Responses Using Real-Time PCR. <i>Methods in Molecular Biology</i> , 2014, 1186, 65-74.	0.9	2
149	Melanoma vaccines: in search of a clinical paradigm. <i>Melanoma Research</i> , 2007, 17, 137-138.	1.2	1
150	Pilot trial of a type I - polarized autologous dendritic cell vaccine incorporating tumor blood vessel antigen-derived peptides in patients with metastatic breast cancer. , 2015, 3, .		1
151	CD4+ T-Cell-Mediated Immunity to Cancer. , 2004, , 67-86.		1
152	EphA2: A Novel Target in Renal Cell Carcinoma. , 2009, , 347-366.		1
153	Inhibition of HSPs for Enhanced Immunity. , 2018, , 157-180.		0
154	Neoepitopes as Difference Makers for General Cancer Vaccines?. <i>Clinical Cancer Research</i> , 2020, 26, 4429-4431.	7.0	0
155	Thirty years of therapeutic innovation in melanoma research. <i>Melanoma Research</i> , 2021, 31, 105-107.	1.2	0
156	Dendritic Cell Maturation Versus Polarization in Tumor Escape. , 2009, , 257-268.		0
157	Molecular Immunotherapeutics and Vaccines for Renal Cell Carcinoma and Its Vasculature. , 2013, , 371-383.		0
158	Vaccines in RCC: Clinical and Biological Relevance. , 2015, , 483-525.		0
159	Vascular Normalization, T Cell Trafficking and Anti-tumor Immunity. <i>Resistance To Targeted Anti-cancer Therapeutics</i> , 2016, , 51-76.	0.1	0
160	Poorer survival outcomes in patients with multiple versus single primary melanoma. <i>Cancer</i> , 2022, , .	4.1	0